Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome FoundfiledCriticalWellcome Found
Priority to KR7500221ApriorityCriticalpatent/KR790000405B1/en
Application grantedgrantedCritical
Publication of KR790000405B1publicationCriticalpatent/KR790000405B1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Micro-Organisms Or Cultivation Processes Thereof
(AREA)
Abstract
Recombinant influenza vaccine was prepd. from two kinds of different viruses which have good antigenic and growing properties. Thus, hyperattenuated species were inactivated with IR rays to reduce their original infectivity and then inoculated into the AOS media with pathogenic species. After the culturing, desired recombinant species were sepd. by cloning.
KR7500221A1975-02-031975-02-03Method of manufacturing influenza vaccines
KR790000405B1
(en)